Dov A Goldstein Md insider trades
Open-market stock purchases and sales by Dov A Goldstein Md, Chief Financial Officer at BioAge Labs, Inc, from SEC Form 4 filings since Feb 7, 2012.
Track record: 0% of 1 scored buy are up 5% or more since purchase, averaging -78%.
Recent trades
| Date | Stock | Trade | Value |
|---|---|---|---|
| Apr 23, 2026 | BIOA BioAge Labs, Inc | Bought (not open market) | — |
| Mar 1, 2026 | BIOA BioAge Labs, Inc | Bought (not open market) | — |
| Feb 17, 2026 | BIOA BioAge Labs, Inc | Bought (not open market) | — |
| Feb 1, 2026 | BIOA BioAge Labs, Inc | Bought (not open market) | — |
| Jan 16, 2026 | BIOA BioAge Labs, Inc | Bought (not open market) | — |
| Jan 13, 2026 | BIOA BioAge Labs, Inc | Sold | $165K |
| Jan 13, 2026 | BIOA BioAge Labs, Inc | Sold | $86.4K |
| Jan 13, 2026 | BIOA BioAge Labs, Inc | Sold | $240K |
| Jan 13, 2026 | BIOA BioAge Labs, Inc | Sold | $40.5K |
| Jan 13, 2026 | BIOA BioAge Labs, Inc | Bought (not open market) | — |
| Jan 2, 2026 | COYA Coya Therapeutics, Inc | Bought (not open market) | — |
Companies traded
- BIOA BioAge Labs, Inc: 4 sales, last Apr 23, 2026
- COYA Coya Therapeutics, Inc: 2 buys, last Jan 2, 2026
- GANX Gain Therapeutics, Inc: other filings, last Jun 24, 2025
- NBSE NeuBase Therapeutics, Inc: 3 buys, last Sep 9, 2022
- ADMA Adma Biologics, Inc: other filings, last Feb 28, 2020
- ESPR Esperion Therapeutics, Inc: 1 buy, 5 sales, last Jun 6, 2018
- CEMP Cempra, Inc: 1 buy, 7 sales, last Mar 8, 2017
- LOXO Loxo Oncology, Inc: 2 buys, last Apr 2, 2015
- DRTX Durata Therapeutics, Inc: 1 buy, last Jul 24, 2012
- NONE Adma Biologics, Inc: other filings, last Apr 4, 2012